Sanofi (NASDAQ:SNY) Cut to “Equal Weight” at Barclays

Barclays cut shares of Sanofi (NASDAQ:SNY) from an overweight rating to an equal weight rating in a report published on Tuesday, MarketBeat.com reports.

Several other research firms also recently commented on SNY. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Finally, Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.13 on Tuesday. The company has a current ratio of 1.06, a quick ratio of 0.30 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $49.24 and a two-hundred day simple moving average of $48.86. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The firm has a market cap of $117.39 billion, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 1.21 and a beta of 0.45.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $1.31. The firm had revenue of $15.46 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business’s revenue was down 7.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.25 earnings per share. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisory Services Network LLC increased its holdings in shares of Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after buying an additional 210 shares during the last quarter. Thomasville National Bank grew its position in Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after acquiring an additional 211 shares in the last quarter. Waterfront Wealth Inc. increased its stake in Sanofi by 0.4% in the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after acquiring an additional 214 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in Sanofi by 2.3% in the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after acquiring an additional 226 shares during the last quarter. Finally, HM Payson & Co. raised its position in Sanofi by 3.4% during the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock valued at $342,000 after purchasing an additional 235 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.